Combination of low doses of LBW242 with anti-MM agents induces additive/synergistic MM cell death. (A). MM.1S, MM.1R, or Dox-40 MM cells were treated with indicated doses of LBW242, rhTRAIL, or LBW242 plus rhTRAIL and assessed for viability using MTT assays (mean ± SD; n = 3, P < .005). (B) MM.1S, MM.1R, or Dox-40 cells were treated with LBW242, melphalan, or LBW242 plus melphalan and assessed for viability (mean ± SD; n = 3, P < .005). (C) MM.1S cells were treated with LBW242, melphalan, or LBW242 plus melphalan for 24 hours, and total protein lysates were analyzed for caspase-3 cleavage by Western blot analysis. (D) MM.1S or MM.1R cells were treated with LBW242, Dex, or LBW242 plus Dex for 24 hours and assessed for viability (mean ± SD; n = 3, P < .006). (E) MM.1S or MM.1R cells were treated with LBW242, bortezomib, or LBW242 plus bortezomib for 24 hours and assessed for viability (mean ± SD; n = 3, P < .005). (F) MM.1S cells were treated with LBW242, NPI-0052, or LBW242 plus NPI-0052 for 24 hours and assessed for viability (mean ± SD; n = 3, P < .004).